BioCentury
ARTICLE | Company News

OxiGene, Jomed in restenosis deal

September 4, 2001 7:00 AM UTC

OxiGene (OXGN; SSE:OXGN) and Jomed (SWX:JOM) will integrate JOM's stent technology with OXGN's platform of vascular targeting agents (VTAs) to test the VTAs' ability to prevent restenosis following an...